China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.
You may also be interested in...
Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this field.
Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.
A devoted researcher or a shrewd business entrepreneur, whatever you call him, He Jiankui seems to have what it takes to draw the spotlight to his cutting edge gene editing technology, so controversial that even his employer has joined calls to denounce him.